Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

  • B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NXO5[mRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnhUZNKSzVyPUCuNFYyKM7:TR?= MVLTRW5ITVJ?
ALL-PO NX33bmk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwME[zOVUh|ryP NVT2NYhzW0GQR1XS
697 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEm5O|Yh|ryP M4HM[3NCVkeHUh?=
NCI-H748 MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDITWM2OD1yLkGwN|M1KM7:TR?= MmK4V2FPT0WU
NKM-1 NEj2[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMUC5NVIh|ryP MVzTRW5ITVJ?
ES1 MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqyd4pOUUN3ME2wMlEyOjV3IN88US=> MnO2V2FPT0WU
NCI-H1963 MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMUG1O|kh|ryP Mor6V2FPT0WU
NCI-H1417 NH\vb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HNZmlEPTB;MD6xNlk4PCEQvF2= MXrTRW5ITVJ?
NEC8 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMUO1Nlch|ryP M2L5WnNCVkeHUh?=
CRO-AP2 NWHjbYlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\YbZNKSzVyPUCuNVY5QDlizszN M3naPXNCVkeHUh?=
A3-KAW MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMUe2Nlch|ryP M32xbHNCVkeHUh?=
SF539 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnmyTWM2OD1yLkG5OVk{KM7:TR?= NInYdZhUSU6JRWK=
NOS-1 M4PEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\rbWlEPTB;MD6xPVYyQSEQvF2= MkXHV2FPT0WU
NTERA-S-cl-D1 NYPPWWpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HG[GlEPTB;MD6yNFEyOyEQvF2= NX3Yb4RMW0GQR1XS
COR-L88 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HBWGlEPTB;MD6yNlk2QSEQvF2= MljaV2FPT0WU
EM-2 M{PWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMkSwO|kh|ryP MnvvV2FPT0WU
KARPAS-45 NVjNTnZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2OwfGlEPTB;MD6yO|g{OyEQvF2= NFXhOWRUSU6JRWK=
DSH1 NUj4fYtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnftTWM2OD1yLkK4O|A5KM7:TR?= NUm1OVNyW0GQR1XS
HT-144 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHNTWM2OD1yLkOwNlU3KM7:TR?= MoPrV2FPT0WU
ATN-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nYPGlEPTB;MD6zNFU4PiEQvF2= MmC1V2FPT0WU
HEL M3r3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G4S2lEPTB;MD6zNVM1QCEQvF2= M17yfHNCVkeHUh?=
NB12 NWXRUGxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrSeHdKSzVyPUCuN|E4PTZizszN NILIem5USU6JRWK=
LU-139 NVTuV|AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7DTWM2OD1yLkOzOVEh|ryP MoDmV2FPT0WU
J-RT3-T3-5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\xTWl{UUN3ME2wMlM{PzF4IN88US=> M2PON3NCVkeHUh?=
MOLT-13 NYrad5V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFqzbFlKSzVyPUCuN|M5OSEQvF2= MmnTV2FPT0WU
SR NIHKXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj1TWM2OD1yLkO0NlYyKM7:TR?= MoOxV2FPT0WU
CMK NF:3ZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwM{W3Nlch|ryP MV7TRW5ITVJ?
ES8 M2\Kemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfVTWM2OD1yLkO2NFIzKM7:TR?= NFrGdXFUSU6JRWK=
LB647-SCLC NEPQV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwM{[3N{DPxE1? MmjHV2FPT0WU
TE-8 NXTib|BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\pSmlEPTB;MD6zOlk{PSEQvF2= NX;UcphqW0GQR1XS
BV-173 NYDqdVlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WxVWlEPTB;MD6zO|EzOSEQvF2= M4D3SHNCVkeHUh?=
DEL M3K3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3ZT3VKSzVyPUCuN|c1QDdizszN MUfTRW5ITVJ?
ARH-77 NWnuXIZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvqWGZKSzVyPUCuN|gyQTNizszN NETnRnJUSU6JRWK=
NCCIT NWTqVXd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwM{i2OFkh|ryP M{fXWXNCVkeHUh?=
RPMI-8402 NIXSSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O4O2lEPTB;MD6zPFcxOSEQvF2= NUnqbnVZW0GQR1XS
MONO-MAC-6 M1fKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOwWoJKSzVyPUCuN|g4PzZizszN M{jTTnNCVkeHUh?=
SK-MM-2 M4P4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X2NmlEPTB;MD6zPVg3QCEQvF2= MVLTRW5ITVJ?
CHP-126 M2rIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK1TWM2OD1yLkSwNlMyKM7:TR?= NWftcJQ6W0GQR1XS
A101D MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwNECzJO69VQ>? Mn[2V2FPT0WU
SCH NVzUdIRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET2T4dKSzVyPUCuOFA{PDJizszN NWLCW4cxW0GQR1XS
NMC-G1 NH\FT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni2TWM2OD1yLkSwN|Y4KM7:TR?= MlHSV2FPT0WU
NCI-H209 NVHJS49tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfWfHdKSzVyPUCuOFA3OTNizszN M17tVHNCVkeHUh?=
MOLT-16 M4L6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnF[21xUUN3ME2wMlQyODF5IN88US=> NGHiS5VUSU6JRWK=
RPMI-6666 NWHPS2tCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHGZYdXUUN3ME2wMlQyOTJizszN MnHDV2FPT0WU
OPM-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TsTmlEPTB;MD60NVUyOyEQvF2= NGnOTHZUSU6JRWK=
MRK-nu-1 MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m2d2lEPTB;MD60N|E2OyEQvF2= MUXTRW5ITVJ?
BC-1 Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S3[mlEPTB;MD60N|QxOyEQvF2= NWPDZlNpW0GQR1XS
MHH-NB-11 NH75[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO4R3c3UUN3ME2wMlQ{PDV|IN88US=> M2WyVnNCVkeHUh?=
Ramos-2G6-4C10 MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDxTWM2OD1yLkSzPFk4KM7:TR?= NIKzeVVUSU6JRWK=
LS-513 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwNES1NFEh|ryP MWfTRW5ITVJ?
K5 NWf4W|BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn4ZmlKSzVyPUCuOFcxOjVizszN MYHTRW5ITVJ?
HOP-62 M{\YbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\yTWM2OD1yLkS4N|U5KM7:TR?= NIK1RVdUSU6JRWK=
NCI-H187 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;kd4ZGUUN3ME2wMlQ6OjJ5IN88US=> MlrDV2FPT0WU
BE-13 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTCdYs2UUN3ME2wMlQ6PjZzIN88US=> Mn7IV2FPT0WU
HC-1 NYrs[FlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFSyO|JKSzVyPUCuOVA1PzNizszN MYPTRW5ITVJ?
ACN M33Wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKxTWM2OD1yLkWxNFI5KM7:TR?= MUTTRW5ITVJ?
HCC1599 MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\ifWlEPTB;MD61NVU4KM7:TR?= MVPTRW5ITVJ?
MV-4-11 M1zUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17aeWlEPTB;MD61N|A1OSEQvF2= NHu2OXBUSU6JRWK=
LC-2-ad MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TENGlEPTB;MD61N|Y3OyEQvF2= Mnf2V2FPT0WU
HL-60 MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHpbHMyUUN3ME2wMlU1OjZzIN88US=> MVTTRW5ITVJ?
NB17 NWnFfm1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjUeYtRUUN3ME2wMlU1OzhizszN M1;3e3NCVkeHUh?=
TE-1 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwNUWzNFYh|ryP NVu2ZpNlW0GQR1XS
NCI-H524 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DJbmlEPTB;MD61OVQxOSEQvF2= MV;TRW5ITVJ?
MZ7-mel MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwNU[xNFUh|ryP MnzlV2FPT0WU
L-363 M4PS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjpOZVuUUN3ME2wMlU3PjV5IN88US=> MXHTRW5ITVJ?
BL-41 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjKem83UUN3ME2wMlU3QDh7IN88US=> MmnwV2FPT0WU
LU-134-A M3XVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjrTWM2OD1yLkW3NFc{KM7:TR?= MoLwV2FPT0WU
SIG-M5 MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nPTmlEPTB;MD61O|g1QCEQvF2= MXfTRW5ITVJ?
ONS-76 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXz[otbUUN3ME2wMlU5OjR{IN88US=> M{nEU3NCVkeHUh?=
KARPAS-299 NVLhWm5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7yR49KSzVyPUCuOVg2ODRizszN NWTUNJV2W0GQR1XS
DU-4475 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe0cG5KSzVyPUCuOVg4ODNizszN MlvhV2FPT0WU
NB69 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfkcZZ1UUN3ME2wMlU6QDJ3IN88US=> MVLTRW5ITVJ?
MHH-PREB-1 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\UTWM2OD1yLk[wO|E6KM7:TR?= NUHYO3gzW0GQR1XS
LU-165 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDQTWM2OD1yLk[xPFEzKM7:TR?= MX;TRW5ITVJ?
LOUCY M17BU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[xdWlEPTB;MD62N|M3PCEQvF2= MXnTRW5ITVJ?
NCI-H526 NWLLN2NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnwcll2UUN3ME2wMlY{PTRzIN88US=> NGnJN3VUSU6JRWK=
KE-37 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvlTWM2OD1yLk[0Nlc3KM7:TR?= M2Ow[XNCVkeHUh?=
NALM-6 M3rqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwNkS4OkDPxE1? M3LhUHNCVkeHUh?=
CW-2 M{GzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PP[mlEPTB;MD62OVc6PCEQvF2= MYPTRW5ITVJ?
SU-DHL-1 NHz0WY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHBOFBiUUN3ME2wMlY2QTR5IN88US=> MWLTRW5ITVJ?
NB13 M2TKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwNk[4NVch|ryP MYDTRW5ITVJ?
QIMR-WIL M1zUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXpS3JsUUN3ME2wMlY5OzR|IN88US=> M1rhOHNCVkeHUh?=
ECC12 NH63cWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj6TWM2OD1yLkewNFg3KM7:TR?= M3i5PXNCVkeHUh?=
KALS-1 M1T1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi5TWM2OD1yLkewOFkzKM7:TR?= MWDTRW5ITVJ?
COR-L279 M1TkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXyTWM2OD1yLkewPVk3KM7:TR?= MkHPV2FPT0WU
NB14 NVztW41JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXKd4lXUUN3ME2wMlczPjF5IN88US=> MULTRW5ITVJ?
CCRF-CEM NYPre5gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPuTWM2OD1yLke0OlYyKM7:TR?= MXHTRW5ITVJ?
SW954 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fM[WlEPTB;MD63OVk6QSEQvF2= MoTyV2FPT0WU
IST-SL1 M{fDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvEUGRKSzVyPUCuO|c{PDhizszN NYL4eG1lW0GQR1XS
LAMA-84 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPFelNtUUN3ME2wMlc4PTZ5IN88US=> MWLTRW5ITVJ?
Daudi MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwN{e2PFEh|ryP NFHOVWJUSU6JRWK=
BC-3 NHLwc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwN{izNFgh|ryP NG\vR3pUSU6JRWK=
HCC2998 MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfLTWM2OD1yLke4N|Yh|ryP M{PFUXNCVkeHUh?=
NCI-H69 MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwOECxOFch|ryP M{fhb3NCVkeHUh?=
CPC-N MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\HfmtKSzVyPUCuPFA2OjRizszN Mm\GV2FPT0WU
NOMO-1 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP6TohKSzVyPUCuPFExQDRizszN M4XH[HNCVkeHUh?=
CESS M33pdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwOEGxPVch|ryP M{PHXXNCVkeHUh?=
LC4-1 NIfKNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zibGlEPTB;MD64OFAxPyEQvF2= MX3TRW5ITVJ?
BL-70 M2PkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDQXIc{UUN3ME2wMlg2PzB{IN88US=> NF6zd5ZUSU6JRWK=
ES4 NU[xWWx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon5TWM2OD1yLki1PFY5KM7:TR?= MXjTRW5ITVJ?
HCE-T NH;FTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzYOGxKSzVyPUCuPFcyPzFizszN MVjTRW5ITVJ?
JAR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwOEe4Nlch|ryP NVq0[VRqW0GQR1XS
ST486 NHq5WnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3oOWdbUUN3ME2wMlg4QTF5IN88US=> NYHVfJlDW0GQR1XS
KS-1 M{jGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDue2t5UUN3ME2wMlg5ODl4IN88US=> M3K2V3NCVkeHUh?=
GDM-1 NFPodYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XSb2lEPTB;MD64PFY5PyEQvF2= NWfWZ2F2W0GQR1XS
EHEB NVfTdlFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f1[GlEPTB;MD65NlU5PSEQvF2= MXrTRW5ITVJ?
LB2518-MEL M{HVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXEUHZKSzVyPUCuPVMzQDRizszN NUTVbXo2W0GQR1XS
GOTO MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwOUWwO|Yh|ryP NH;WXoZUSU6JRWK=
LXF-289 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDTTWM2OD1yLkm1PVAyKM7:TR?= MXLTRW5ITVJ?
ES6 NFPWT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLxTWM2OD1yLkm2OFM4KM7:TR?= MkT3V2FPT0WU
OS-RC-2 MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7nWoJKSzVyPUCuPVY5OyEQvF2= MlflV2FPT0WU
DMS-153 M4OzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj0TWM2OD1yLkm3OFY6KM7:TR?= M1[1NXNCVkeHUh?=
SK-PN-DW MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwOUe4N|Eh|ryP NXTHTW9bW0GQR1XS
HH NVG1S5pNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TPZmlEPTB;MD65PFk2QSEQvF2= MmnRV2FPT0WU
SH-4 M4rCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVeyVIZ7UUN3ME2xMlAzPDFizszN M4LheXNCVkeHUh?=
MOLT-4 MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfiTWM2OD1zLkCzOFU1KM7:TR?= NHjJfXlUSU6JRWK=
TGW MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfFdY1vUUN3ME2xMlA4Pjd3IN88US=> MV7TRW5ITVJ?
L-540 NEPVd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXzTWM2OD1zLkGwOlA1KM7:TR?= M4njdHNCVkeHUh?=
PF-382 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwMUG1NVMh|ryP M1XzXXNCVkeHUh?=
LC-1F NWX4Xm9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwMUKwNFch|ryP Ml7IV2FPT0WU
OVCAR-4 NHjEVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTQ[GpVUUN3ME2xMlE{OTZ3IN88US=> MWrTRW5ITVJ?
A4-Fuk MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D5UWlEPTB;MT6xOVM3PCEQvF2= M1zEUXNCVkeHUh?=
HCC2218 M{jK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwMU[2OFEh|ryP M{m4b3NCVkeHUh?=
HAL-01 NVOyWm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7nSHFKSzVyPUGuNVY6PDNizszN NGC4UJVUSU6JRWK=
IST-MEL1 M2TqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFwMUe2OVkh|ryP MUTTRW5ITVJ?
NCI-H719 Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL6ZoNKSzVyPUGuNVc5QThizszN MUfTRW5ITVJ?
EVSA-T MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC5VXZOUUN3ME2xMlE5OTF2IN88US=> MWnTRW5ITVJ?
SK-NEP-1 MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K0[WlEPTB;MT6yNFI3PiEQvF2= MkDpV2FPT0WU
OCUB-M MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\Vb4RqUUN3ME2xMlIyPDh7IN88US=> MkT5V2FPT0WU
MEG-01 NWjvdYdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonITWM2OD1zLkKyNVE5KM7:TR?= M1vLZXNCVkeHUh?=
no-10 NXHvTpNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XvWWlEPTB;MT6yN|EyOiEQvF2= MXXTRW5ITVJ?
MHH-CALL-2 M4LTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwMkS3NlEh|ryP M4DX[HNCVkeHUh?=
SK-N-DZ NE\YeYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHFXnl6UUN3ME2xMlI1Pzd4IN88US=> MXjTRW5ITVJ?
SCLC-21H NETYcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXtUHZ[UUN3ME2xMlI3PDd6IN88US=> NE\aPHpUSU6JRWK=
CTV-1 NUnwO4VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLSZ5hsUUN3ME2xMlI4PDJ3IN88US=> MUDTRW5ITVJ?
NB1 MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwMke3N|Ih|ryP NVj3eJQ3W0GQR1XS
NCI-H64 MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[zR29KSzVyPUGuNlg1PjJizszN MX;TRW5ITVJ?
MDA-MB-134-VI NEnI[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fRXGlEPTB;MT6yPFU4PyEQvF2= MUjTRW5ITVJ?
LB2241-RCC NGXVOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDzUIZKSzVyPUGuNlg3PjNizszN M{TDPXNCVkeHUh?=
8-MG-BA MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFwMki4OlYh|ryP NVexVoxyW0GQR1XS
LP-1 Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fySWlEPTB;MT6yPVk1PyEQvF2= MX;TRW5ITVJ?
LS-411N NH75TpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3OTWM2OD1zLkOwPVk5KM7:TR?= NWXSZmZwW0GQR1XS
CAL-148 M{W4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C5ZmlEPTB;MT6zNlU1OiEQvF2= NUPmVmVbW0GQR1XS
NCI-H2171 NV\RRWd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f1cWlEPTB;MT6zOFUxOiEQvF2= NUnpUoVxW0GQR1XS
JiyoyeP-2003 MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPvV5ZGUUN3ME2xMlM2OzlizszN NVvGUm5rW0GQR1XS
NCI-H2107 Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojLTWM2OD1zLkO1PFg{KM7:TR?= Ml;BV2FPT0WU
BB30-HNC NUnVSW1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrJWJNJUUN3ME2xMlM5QTd6IN88US=> NIPtd29USU6JRWK=
K-562 MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHuTWM2OD1zLkO5NlE6KM7:TR?= NETKNZBUSU6JRWK=
PSN1 M4XVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFwNEKyPFch|ryP NHToeWZUSU6JRWK=
HCC2157 NV;rVnhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Htd2lEPTB;MT60NlY6OSEQvF2= MWfTRW5ITVJ?
SBC-1 NIS1eo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nKXGlEPTB;MT60Nlc1OSEQvF2= NHHD[mRUSU6JRWK=
MC116 NGfDclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFwNEO2NVUh|ryP MUXTRW5ITVJ?
KARPAS-422 M2rMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;yeY9bUUN3ME2xMlQ2OzV6IN88US=> MlrBV2FPT0WU
LB996-RCC Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFwNEexNFMh|ryP NW\3XYViW0GQR1XS
MSTO-211H M1vUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFwNEe5PFch|ryP MVrTRW5ITVJ?
BT-474 NGDZNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFwNUG3OlQh|ryP NYrINYU6W0GQR1XS
A388 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn5[FVoUUN3ME2xMlUyQTR3IN88US=> M3fZWnNCVkeHUh?=
SJSA-1 M3fwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HXcWlEPTB;MT61NlI3KM7:TR?= M3LqNHNCVkeHUh?=
COLO-829 NXPOVnhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\Z[2ZIUUN3ME2xMlU{PTZ2IN88US=> M161SnNCVkeHUh?=
KM-H2 M2jkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjVZolKSzVyPUGuOVY3PyEQvF2= M4W1Z3NCVkeHUh?=
GR-ST M4TaU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Xk[GlEPTB;MT61OlgzKM7:TR?= MkK3V2FPT0WU
RPMI-8866 M4L3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP2SHBYUUN3ME2xMlYxOTR2IN88US=> MYrTRW5ITVJ?
KG-1 M{HITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nPeGlEPTB;MT62NVkxOSEQvF2= NUDkeWNYW0GQR1XS
NCI-H82 NUK0WFZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTacJpwUUN3ME2xMlY{PDB4IN88US=> NUPV[Zo2W0GQR1XS
LB1047-RCC M4ntPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3UWY1KSzVyPUGuOlM1PTlizszN NWr4OYV2W0GQR1XS
KM12 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\3XGlEPTB;MT62OFch|ryP NIDXTFFUSU6JRWK=
NB5 Mk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPrNHpKSzVyPUGuOlU3PzdizszN NXywRVFpW0GQR1XS
HDLM-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjiTWM2OD1zLk[4NlgyKM7:TR?= Mn60V2FPT0WU
KU812 NEXkeIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\WdmlEPTB;MT62PVYxPSEQvF2= NEjSeo1USU6JRWK=
DB NXrZNHZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwN{CzOVMh|ryP NE\JVYFUSU6JRWK=
HD-MY-Z M{PXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXiNHRKSzVyPUGuO|UzOzRizszN MXjTRW5ITVJ?
KURAMOCHI NFq0eFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFwN{eyNFch|ryP MnP2V2FPT0WU
ETK-1 NGT5RZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfPTWM2OD1zLke4PFc6KM7:TR?= Moq5V2FPT0WU
SK-UT-1 NHHaU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfsdpoyUUN3ME2xMlc6Ozh6IN88US=> NF3NbXZUSU6JRWK=
HUTU-80 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[1TWM2OD1zLke5OVA5KM7:TR?= M1TxU3NCVkeHUh?=
ES7 NH7lUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PQcmlEPTB;MT64NFMxOiEQvF2= NFfUfGJUSU6JRWK=
SW872 NF7CXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HKe2lEPTB;MT64NVM6PSEQvF2= Mn73V2FPT0WU
TK10 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\UNoZKSzVyPUGuPFMyODhizszN MmOxV2FPT0WU
LB831-BLC M{XUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDqTWM2OD1zLkizOVY{KM7:TR?= NGnqNHBUSU6JRWK=
TE-9 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXJTWM2OD1zLki0OFIzKM7:TR?= MUjTRW5ITVJ?
MLMA NEPYZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zXZ2lEPTB;MT64PFI{PCEQvF2= MXvTRW5ITVJ?
D-542MG NF;YSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi5cIluUUN3ME2xMlg6Ozd|IN88US=> M4LiTXNCVkeHUh?=
EW-16 NEnFUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\3TWM2OD1zLkmyO|Ih|ryP Mn34V2FPT0WU
LOXIMVI NHXHUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPLdWJKSzVyPUGuPVMzQCEQvF2= MmPVV2FPT0WU
GB-1 Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjETWM2OD1zLkmzPFY3KM7:TR?= MVXTRW5ITVJ?
IST-SL2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfVTHlRUUN3ME2yMlAxOjZ{IN88US=> M{T4dnNCVkeHUh?=
LAN-6 M{nHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnoT5dKSzVyPUKuNFE6PjZizszN NXvJV3dkW0GQR1XS
NCI-H510A NYfXO5JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3roSmlEPTB;Mj6wOFUxOiEQvF2= M3TjbHNCVkeHUh?=
NCI-H1092 NVfOUlV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHQTWM2OD1{LkC1NVI1KM7:TR?= NGW0NWJUSU6JRWK=
HT NVnQPFR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\UVmNKSzVyPUKuNVA1PTRizszN NXTWT3h2W0GQR1XS
RL95-2 NGS3[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvLTWM2OD1{LkGxOFgzKM7:TR?= M3vvcnNCVkeHUh?=
NCI-H1355 M{LCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrxbI56UUN3ME2yMlEyPzl{IN88US=> M3zkRXNCVkeHUh?=
NCI-H720 NWe2[ZZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjsN2dKSzVyPUKuNVY5PzNizszN NULRPHM5W0GQR1XS
NCI-H1522 M{LlZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P3[2lEPTB;Mj6yNVczOyEQvF2= MmrUV2FPT0WU
LB373-MEL-D M1TOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nQR2lEPTB;Mj6yOlkxOiEQvF2= Ml;OV2FPT0WU
DG-75 NHG1[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf4[lBqUUN3ME2yMlI4OTR6IN88US=> M17OOXNCVkeHUh?=
ML-2 NVfhRoE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK4cndKSzVyPUKuN|I5PTVizszN NX6xPIx[W0GQR1XS
SF126 M4nKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LHcWlEPTB;Mj6zN|A6PCEQvF2= M2r2cnNCVkeHUh?=
MPP-89 M4fZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfOOHd[UUN3ME2yMlM{OTR3IN88US=> NHLsPFJUSU6JRWK=
NCI-H345 M{fBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP1TWM2OD1{LkOzNlc4KM7:TR?= NF61NGhUSU6JRWK=
LS-123 M2nXUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHwPGsyUUN3ME2yMlM1QTN4IN88US=> MYnTRW5ITVJ?
NB10 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7yblV1UUN3ME2yMlQyODl{IN88US=> MWrTRW5ITVJ?
CGTH-W-1 NGG5[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrLTWM2OD1{LkSyNlY4KM7:TR?= NEn6SW5USU6JRWK=
CP66-MEL NGXKVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDqTWM2OD1{LkS3O|ch|ryP NYrQ[YRWW0GQR1XS
L-428 NIjzWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3OzSmlEPTB;Mj60PFUzOSEQvF2= M3nrfXNCVkeHUh?=
DMS-79 M2fXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJwNUSxNFMh|ryP MVLTRW5ITVJ?
NCI-H1882 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSzNGlWUUN3ME2yMlY4PTZ{IN88US=> MVvTRW5ITVJ?
KGN Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHG[ItKSzVyPUKuO|Y5PzZizszN NHrVS5VUSU6JRWK=
EW-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;JOVJiUUN3ME2yMlc4ODh|IN88US=> NF3MNIJUSU6JRWK=
U-266 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn34TWM2OD1{Lki0PFI{KM7:TR?= M3frRXNCVkeHUh?=
COLO-320-HSR Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{iyZ2lEPTB;Mj64OVY1OSEQvF2= M{XUbnNCVkeHUh?=
KMOE-2 M4TVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\TVYtTUUN3ME2yMlg4PzFzIN88US=> M1XE[nNCVkeHUh?=
BB49-HNC NVnKWGJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXhenpHUUN3ME2yMlkzPDhizszN NETYT|FUSU6JRWK=
GI-1 NGHp[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInTeGdKSzVyPUKuPVI6PTdizszN NUfMUJcxW0GQR1XS
NCI-H1304 M2D1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSwTWM2OD1|LkCwOVEyKM7:TR?= MoW2V2FPT0WU
NCI-H2227 M361fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojXTWM2OD1|LkCyNFc6KM7:TR?= M33GeHNCVkeHUh?=
U-87-MG M3zLNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37pW2lEPTB;Mz6wN|UyOyEQvF2= M{KzdXNCVkeHUh?=
NCI-H747 NVfVNHI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MliyTWM2OD1|LkC1NlA3KM7:TR?= M1v3RnNCVkeHUh?=
CTB-1 NVfUNFQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X0bmlEPTB;Mz6wOVM4PiEQvF2= M3TkfHNCVkeHUh?=
RPMI-8226 NFLTOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\QUlJKSzVyPUOuNVQ{PzhizszN NFLaTZFUSU6JRWK=
NCI-H2141 NH[zfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPvc4ljUUN3ME2zMlE3PTZ4IN88US=> MkTGV2FPT0WU
IST-MES1 M2G3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF35SXlKSzVyPUOuNVgzPzlizszN M17ZWnNCVkeHUh?=
TE-5 M2LINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nufWlEPTB;Mz6yNVM1OiEQvF2= MljWV2FPT0WU
UACC-257 M2i2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHye3VKSzVyPUOuOFM3PTlizszN MUTTRW5ITVJ?
SK-N-FI MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XUZWlEPTB;Mz60OVIzPyEQvF2= M2jpdXNCVkeHUh?=
MFH-ino MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nPNWlEPTB;Mz60OlU5QSEQvF2= NHnxfWhUSU6JRWK=
SF268 M1T1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzt[25KSzVyPUOuOFgyPzRizszN NGHPbppUSU6JRWK=
TE-12 M2rjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP2cIJbUUN3ME2zMlUyPjl7IN88US=> NEjydldUSU6JRWK=
NB6 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjPSnZxUUN3ME2zMlU2PTZ|IN88US=> NGjVWW1USU6JRWK=
DJM-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq5UJdKSzVyPUOuOVk5QTlizszN M{X5V3NCVkeHUh?=
MZ1-PC M2nwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLQOolKSzVyPUOuOlE3OjRizszN MXjTRW5ITVJ?
OCI-AML2 M2nzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULMfnVRUUN3ME2zMlYzPjdzIN88US=> M{POeXNCVkeHUh?=
NCI-H1155 M4HKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljITWM2OD1|LkewPVQ4KM7:TR?= MUfTRW5ITVJ?
RKO MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNwN{exPFkh|ryP NFLWXVRUSU6JRWK=
ECC4 NVzvXJhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MniyTWM2OD1|Lkm3NVk2KM7:TR?= NVy0OnJNW0GQR1XS
BB65-RCC MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjId3VKSzVyPUOuPVc2PDdizszN NGXYV|NUSU6JRWK=
EB-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPBTIhMUUN3ME2zMlk6PjN|IN88US=> NIO1fYxUSU6JRWK=
SHP-77 M3XzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTRwMEC1NlQh|ryP NX7S[HgyW0GQR1XS
NCI-H2196 MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnPV45mUUN3ME20MlA2PjJ3IN88US=> MkHXV2FPT0WU
GI-ME-N NIXVO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv3[2dKSzVyPUSuNFY{QTlizszN MnfXV2FPT0WU
MN-60 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfLW2hoUUN3ME20MlExQDdizszN NUnpN|V[W0GQR1XS
NCI-H1694 MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j0bWlEPTB;ND6xN|QxPSEQvF2= M1;GRXNCVkeHUh?=
LU-65 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n0O2lEPTB;ND6xOVM{OiEQvF2= NH7IO5pUSU6JRWK=
NCI-H1436 Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTRwMUizN|Mh|ryP NXvRXZhYW0GQR1XS
KINGS-1 NXH2N5U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXjdFFKSzVyPUSuN|E1OzJizszN M2\6VnNCVkeHUh?=
GT3TKB NXfCS2l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fHWGlEPTB;ND6zN|I3QCEQvF2= NVvwPHF2W0GQR1XS
Becker NH;1OVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfTRW5KSzVyPUSuN|c{OTJizszN M2Xh[3NCVkeHUh?=
HCC1187 M125Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M333cGlEPTB;ND64PVY2PyEQvF2= NG\OXWVUSU6JRWK=
D-502MG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK5R3lKSzVyPUWuNFA1OTZizszN NVXOS5BwW0GQR1XS
VA-ES-BJ M3zpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLMTVl1UUN3ME21MlE{Pzd6IN88US=> M1[4b3NCVkeHUh?=
NB7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr0bJNKSzVyPUWuNVQyOTJizszN M1jrOHNCVkeHUh?=
SW962 NETie|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPQTWM2OD13LkO4PFE1KM7:TR?= M4PKSHNCVkeHUh?=
no-11 Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DNSGlEPTB;NT63OlM1OyEQvF2= M4CwSHNCVkeHUh?=
KNS-81-FD M3n2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\WRo1KSzVyPUWuPVA3QTRizszN Mlr6V2FPT0WU
COLO-684 NWP5T|hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnSOm9{UUN3ME21Mlk6PDl2IN88US=> MVzTRW5ITVJ?
D-263MG MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\hZWg2UUN3ME22MlA5QDl3IN88US=> MUjTRW5ITVJ?
EW-24 M3nOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPRV|VKSzVyPU[uNlg2OSEQvF2= NWDye5J5W0GQR1XS
TE-10 M2DibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTZwNEK2NlMh|ryP MXTTRW5ITVJ?
EKVX M3\rNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvhTWM2OD14LkS2N|IyKM7:TR?= MkLyV2FPT0WU
NCI-H1648 M1znUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO5NJRKSzVyPU[uOlc2PTdizszN MmDPV2FPT0WU
LB771-HNC Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTXTWM2OD14LkmyN|AyKM7:TR?= MkDjV2FPT0WU
SK-MEL-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH0d3JKSzVyPUiuNVMyPjZizszN M3vSTnNCVkeHUh?=
COLO-668 MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\EUHBKSzVyPUiuNlc4QDZizszN MlXsV2FPT0WU
EW-12 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTOTWM2OD16LkSwPFA{KM7:TR?= M3\3W3NCVkeHUh?=
A253 NUPRXFFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HFdGlEPTB;OD64OFY3OSEQvF2= Mny2V2FPT0WU
NCI-H2126 NVrNNYFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\XS2lEPTB;OD64PVMyQSEQvF2= MkPoV2FPT0WU
Calu-6 NEPWZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP0Z2NKSzVyPUiuPVkxPDJizszN NH3GcHNUSU6JRWK=
NCI-H23 NW\QS4ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjScWJ5UUN3ME25MlE4PzR4IN88US=> M1i0RnNCVkeHUh?=
WSU-NHL MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rIdmlEPTB;OT63O|Q4QCEQvF2= MVXTRW5ITVJ?
MMAC-SF NIjEdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;JSoJKSzVyPUmuPVc6ODRizszN M2jxTXNCVkeHUh?=
SK-LMS-1 NFLUZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXqTWM2OD1zMD6yPFM1KM7:TR?= M3vhSnNCVkeHUh?=
GCIY M2K3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\FTWM2OD1zMD61PVI1KM7:TR?= NF\BOJVUSU6JRWK=
TE-15 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESzWopKSzVyPUGxMlYxODRizszN NYLSblRVW0GQR1XS
EoL-1-cell NIPuTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHUTWM2OD1zMT63OlgzKM7:TR?= NY\yRlJYW0GQR1XS
NCI-H2081 M3;QS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L0OWlEPTB;MUGuO|c5PiEQvF2= MXTTRW5ITVJ?
EW-3 NFvnNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NICzenVKSzVyPUGyMlI1PjNizszN MYDTRW5ITVJ?
CAS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Xi[GlEPTB;MUKuN|Y{OSEQvF2= MkG4V2FPT0WU
C2BBe1 NF;rZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF{Lk[xN|Eh|ryP NWHzU|NNW0GQR1XS
D-247MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPtcphKSzVyPUGyMlc6PTJizszN MUnTRW5ITVJ?
NCI-SNU-5 M{DCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv3dmdKSzVyPUGyMlgxOTNizszN NVjSWFNSW0GQR1XS
LS-1034 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF2LkO5O|Uh|ryP NU\2XpR2W0GQR1XS
EW-18 NFfJXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID2dGNKSzVyPUG0MlQ1QCEQvF2= M1;LO3NCVkeHUh?=
Raji NYDRXFhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml61TWM2OD1zND61NFQ6KM7:TR?= MoLyV2FPT0WU
D-283MED MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PLcGlEPTB;MUSuOlI4OSEQvF2= MlzsV2FPT0WU
MZ2-MEL NWK4XWRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF2Lkm2PVYh|ryP NFzyTY1USU6JRWK=
NCI-SNU-16 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX2Rlh[UUN3ME2xOU41PjN|IN88US=> NY\nSox[W0GQR1XS
P30-OHK NV\BfZRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnwUpBkUUN3ME2xO{44QDNzIN88US=> MVPTRW5ITVJ?
RXF393 NYT4UXloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn5TWM2OD1zOT6wNVg3KM7:TR?= MWDTRW5ITVJ?
NCI-H1395 NYLob4dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJyLk[3NFMh|ryP MXPTRW5ITVJ?
U-698-M NFTVfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJyLkewO|Uh|ryP NVTXSI1IW0GQR1XS
NCI-SNU-1 MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLTe25DUUN3ME2yNE44OjJ|IN88US=> MWXTRW5ITVJ?
SW684 M3nOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXVUJdKSzVyPUKxMlE4OTZizszN NIHlWIdUSU6JRWK=
NCI-H716 Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\qOWlEPTB;MkGuN|E2PCEQvF2= M1mzNnNCVkeHUh?=
JVM-2 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJzLkSxN|Mh|ryP M2fheXNCVkeHUh?=
NCI-H1581 NYTWW2NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LBT2lEPTB;MkKuOFE1QCEQvF2= M{\jXnNCVkeHUh?=
CA46 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PGXWlEPTB;M{GuOlk{PiEQvF2= NFfDSpBUSU6JRWK=
SNB75 M2mzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX5OXR5UUN3ME2zN{43PTB|IN88US=> NU\XXW9HW0GQR1XS
KNS-42 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTN3Lkm2NlQh|ryP MYfTRW5ITVJ?
TUR NE\GbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjBNlI6UUN3ME2zOk4xPTJzIN88US=> M4\ONnNCVkeHUh?=
REH NVfSZWFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G5SGlEPTB;M{euPFIyOSEQvF2= M3T4XnNCVkeHUh?=
EW-22 MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqyTWM2OD12Mj6yPFg2KM7:TR?= MV7TRW5ITVJ?
NCI-H446 NE\2WZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDZVlJ3UUN3ME20Nk44QDV|IN88US=> MkDJV2FPT0WU
ES3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjtN2JZUUN3ME20N{4yOzN7IN88US=> M{npTHNCVkeHUh?=
EW-11 M1PiPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17EVWlEPTB;NESuPFIyQCEQvF2= NFTHeZRUSU6JRWK=
RH-1 NFHr[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\6TWM2OD12Nz61PFEzKM7:TR?= M2nCeXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03179930 Recruiting Lymphoma|Relapsed|Refractory Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals June 7 2017 Phase 2
NCT03250273 Recruiting Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreactic Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Syndax Pharmaceuticals|Bristol-Myers Squibb November 6 2017 Phase 2
NCT02453620 Recruiting Breast Adenocarcinoma|HER2/Neu Negative|Invasive Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 6 2015 Phase 1
NCT03552380 Recruiting Renal Cell Carcinoma Roberto Pili|Bristol-Myers Squibb|Syndax Pharmaceuticals|Indiana University School of Medicine|Hoosier Cancer Research Network August 31 2018 Phase 2
NCT03473639 Recruiting Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals September 30 2018 Phase 1
NCT02936752 Recruiting Blasts 21-30 Percent of Bone Marrow Nucleated Cells|Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) April 3 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID